Stanley Druckenmiller’s MoonLake Immunotherapeutics MLTX Stock Holding History

Stanley Druckenmiller’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-87,500	Closed	-$4.39M	–	79
2024 Q1	$4.39M	Buy	+87,500	New	+$4.75M	0.1%	66

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Stanley Druckenmiller's MLTX Position: Q2 2024 in Review

Stanley Druckenmiller sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 87,500 shares — an estimated $4.39M sold.

Stanley Druckenmiller first reported a position in MLTX in Q1 2024 and held it in 1 quarter. The position peaked at $4.39M in Q1 2024. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

Stanley Druckenmiller reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
Stanley Druckenmiller sold 87,500 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $4.39M.
Stanley Druckenmiller first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 1 quarter.
Stanley Druckenmiller's MoonLake Immunotherapeutics position peaked at $4.39M in Q1 2024.
111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on Duquesne Family Office's 13F filing for Q2 2024, filed 14 Aug 2024.